Topic: infectious respiratory diseases
Armed with positive phase 2b data, resTORbio is planning pivotal trials next year for a drug to prevent respiratory tract infections in the elderly.
Qiagen will gain control of a pipeline of assay panels designed to diagnose infections affecting the respiratory and gastrointestinal systems.
Boston biotech resTORbio raised $40 million aimed at taking its lead candidate for respiratory tract infections in elderly patients into phase 3.
Just days after their lead drug-device combination was voted down by FDA advisors, Nektar and Bayer were hit by a phase 3 failure in another program.
Startup Vir Biotechnology, guided by former Biogen CEO George Scangos, is unveiling a multifaceted pipeline of treatments for infectious diseases.
Shares in U.K. biotech Synairgen were pummeled today as partner AstraZeneca revealed it was stopping development of its inhaled interferon beta therapy AZD9412.
Sanofi has paid €120 million upfront and committed to up to €495 million more for a stake in AstraZeneca’s experimental monoclonal antibody against RSV.
It’s the fourth-quarter clear out, and AstraZeneca has pulled the plug on a combo of its immuno-oncology candidate as well as axing a test of its biologic arm’s RSV drug as it sheds some more light on its tests in head and neck cancers.
Aviragen was pummeled in after-hours trading yesterday when it revealed one of its lead antiviral candidates had missed the mark in a phase 2a trial.